Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Antibody shows promise in eosinophilic gastritis/duodenitis

Key clinical point: Antibody could be safer than steroids for long-term treatment.

Major finding: Eosinophils dropped by 86% in the treatment group and increased by 9% in controls.

Study details: A phase 2, randomized, controlled trial (n = 65).

Disclosures: The study was funded by Alkalos. Dr. Semrad has no relevant financial disclosures.

Citation:

Dellon ES et al. N Engl J Med. 2020 Oct 22. doi: 10.1056/NEJMoa2012047